We are live on ! Find out more
BIOR

Biora Therapeutics, Inc. Common Stock

Delisted

BIOR was delisted on the 10th of December, 2024.

30 hedge funds and large institutions have $6.46M invested in Biora Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

782% more call options, than puts

Call options by funds: $3.24M | Put options by funds: $367K

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

26% less capital invested

Capital invested by funds: $8.72M → $6.46M (-$2.26M)

29% less funds holding

Funds holding: 4230 (-12)

63% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 19

Holders
30
Holders Change
-12
Holders Change %
-28.57%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
8
Reduced
6
Closed
19
Calls
$3.24M
Puts
$367K
Net Calls
+$2.87M
Net Calls Change
+$2.71M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1
Athyrium Capital Management
New York
$4.69M
Vanguard Group
2
Vanguard Group
Pennsylvania
$667K +$15.6K +461 +2%
BlackRock
3
BlackRock
New York
$180K
GCP
4
GSA Capital Partners
United Kingdom
$159K -$88.4K -2,608 -31%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$122K -$34 -1 -0%
SSA
6
Schonfeld Strategic Advisors
New York
$118K +$144K +4,250 New
Creative Planning
7
Creative Planning
Kansas
$58.2K +$71.2K +2,100 New
LPL Financial
8
LPL Financial
California
$57.4K +$67.1K +1,980 +2,152%
State Street
9
State Street
Massachusetts
$48.7K
BCM
10
Bridgeway Capital Management
Texas
$47.9K
CF
11
Cantor Fitzgerald
New York
$45.4K +$55.6K +1,640 New
CIBC Asset Management
12
CIBC Asset Management
Ontario, Canada
$41.9K +$51.2K +1,511 New
Group One Trading
13
Group One Trading
Illinois
$36.4K +$39.6K +1,169 +812%
Millennium Management
14
Millennium Management
New York
$35K -$209K -6,162 -83%
Northern Trust
15
Northern Trust
Illinois
$31.3K +$8.88K +262 +30%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$30K +$7.8K +230 +27%
VF
17
Virtu Financial
New York
$29K +$36.1K +1,064 New
Barclays
18
Barclays
United Kingdom
$16.1K
Morgan Stanley
19
Morgan Stanley
New York
$13.9K +$15K +442 +725%
Wells Fargo
20
Wells Fargo
California
$11K +$8.21K +242 +157%
JP Morgan Chase
21
JP Morgan Chase
New York
$6K +$7.59K +224 New
Simplex Trading
22
Simplex Trading
Illinois
$5K +$2.88K +85 +65%
Citadel Advisors
23
Citadel Advisors
Florida
$3.84K -$17.2K -508 -79%
Osaic Holdings
24
Osaic Holdings
Arizona
$1.9K
TRCT
25
Tower Research Capital (TRC)
New York
$1K -$6.51K -192 -79%

BIOR Hedge Fund Activity: Q1 2023 in Review

30 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q1 2023, worth a combined $6.46M — down 26% from $8.72M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of BIOR and 7 opened new positions — a net loss of 12 holders — while 6 trimmed existing stakes and 8 added.

The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $144K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.1M sold.

  • 30 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q1 2023, down from 42 in Q4 2022.
  • Funds reported $6.46M of Biora Therapeutics, Inc. Common Stock stock for Q1 2023, down 26% quarter-over-quarter.
  • 7 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q1 2023 and 19 closed out, a net change of -12 holders.
  • The largest Biora Therapeutics, Inc. Common Stock buyer in Q1 2023 was Schonfeld Strategic Advisors, an estimated $144K added.
  • The largest Biora Therapeutics, Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $1.1M sold.

Based on aggregated 13F filings for Q1 2023.